Published: Ryan Cross Globe Staff, Updated February 15, 2023, 5:39 a.m.
“It’s night and day,” said Dr. Martin Tolar, who has been chief executive of Alzheon for 10 years. The Framingham-based company is in the advanced stages of testing a drug in people whose genes increase their risk of developing Alzheimer’s.
“It will open up the whole field,” said Dr. Philip Scheltens, head of the Dementia Fund at the health care investment firm EQT Life Sciences. “The graveyard, and the grave mood, has been lifted.”